← Back to Search

Janus Kinase (JAK) Inhibitor

INCB054707 for Vitiligo

Phase 2
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from week 25 up to week 76
Awards & highlights

Study Summary

This trial will test a new drug to see if it works better than a placebo at treating vitiligo over a 24-week period, followed by a 28-week extension.

Eligible Conditions
  • Vitiligo

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from week 25 up to week 76
This trial's timeline: 3 weeks for screening, Varies for treatment, and from week 25 up to week 76 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24
Secondary outcome measures
Extension Period: Number of Participants With Any TEAE
Percentage of Participants Achieving T-VASI50 at Week 24
Placebo-controlled Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

Side effects data

From 2019 Phase 2 trial • 10 Patients • NCT03569371
30%
Upper respiratory tract infection
10%
Rash
10%
Night sweats
10%
Nausea
10%
Fibromyalgia
10%
Headache
10%
Anxiety
100%
80%
60%
40%
20%
0%
Study treatment Arm
INCB054707

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: INCB054707 Dose CExperimental Treatment1 Intervention
Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2).
Group II: INCB054707 Dose BExperimental Treatment1 Intervention
Participants will receive INCB054707 Dose B for 52 weeks (Period 1 + Period 2).
Group III: INCB054707 Dose A followed by Dose CExperimental Treatment1 Intervention
Participants will receive INCB054707 Dose A for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
Group IV: Placebo followed by INCB054707 Dose CPlacebo Group1 Intervention
Participants will receive placebo for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INCB054707
2018
Completed Phase 2
~530

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
364 Previous Clinical Trials
54,994 Total Patients Enrolled
9 Trials studying Vitiligo
2,341 Patients Enrolled for Vitiligo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research include individuals who are over 30 years old?

"The age limit for this particular study is 18-75. If an applicant falls outside of that range, there are 10 other trials for those under 18 and 36 options available for individuals over 65."

Answered by AI

Has INCB054707 received regulatory approval from the FDA?

"INCB054707's safety was given a score of 2 by our team at Power. This is because, while there is some data supporting its safety, none of it suggests that the drug is effective."

Answered by AI

How can I sign up to take part in this research?

"The eligibility requirements for this study include a diagnosis of vitiligo and being 18-75 years old. Up to 171 participants will be enrolled in the trial."

Answered by AI

In how many different medical clinics is this medical study being run today?

"So far, this trial has recruited 39 patients from across the country. Some notable enrolment locations include Investigative Site 023 in Minneapolis, Investigative Site 033 in Dallas, and Investigative Site 005 in Tampa."

Answered by AI

Are investigators actively looking for participants right now?

"According to the website clinicaltrials.gov, this specific trial is not currently recruiting patients. The listing for this study was created on May 6th, 2021 and updated September 14th, 2022. At the moment, there are 41 other trials that are actively looking for participants."

Answered by AI

Who else is applying?

What state do they live in?
Arizona
Tennessee
Louisiana
Other
How old are they?
< 18
18 - 65
What site did they apply to?
Investigative Site 010
Investigative Site 015
Investigative Site 001
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
2

Why did patients apply to this trial?

I have several skin conditions and vitalgo is the one that I could most likely cure.
PatientReceived 1 prior treatment

How responsive is this trial?

Typically responds via
Phone Call
Most responsive sites:
  1. Investigative Site 001: < 24 hours
  2. Investigative Site 024: < 24 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
2021. "A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04818346.
~44 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top